Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Radnor, Pennsylvania, focused on developing innovative therapies for hypertension and related cardiovascular conditions. The company's robust pipeline is designed to address significant unmet medical needs in this sector, reflecting its dedication to enhancing patient care and treatment outcomes. With a strategic emphasis on advancing its drug candidates and a commitment to transforming the therapeutic landscape for chronic cardiovascular diseases, Mineralys presents an attractive opportunity for institutional investors seeking to engage with pioneering advancements in healthcare. Show more
Location: 150 N. RADNOR CHESTER RD., RADNOR, PA, UNITED STATES, 19087, Radnor, PA, 19087, USA | Website: https://mineralystx.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE
Market Cap
2.233B
52 Wk Range
$8.24 - $47.65
Previous Close
$28.21
Open
$28.98
Volume
1,280,451
Day Range
$28.42 - $30.19
Enterprise Value
1.83B
Cash
217.6M
Avg Qtr Burn
-28.87M
Insider Ownership
1.50%
Institutional Own.
-
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Lorundrostat Details Hypertension | NDA Submission | |
Lorundrostat Details Obstructive sleep apnea, Hypertension | Phase 2 Data readout | |
Lorundrostat Details Hypertension and comorbid chronic kidney disease (CKD) | Phase 2 Update |
